The Association of the Lymphocyte-to-C-Reactive-Protein Ratio With Gastric Cancer Patients Who Receive Curative Treatment
Toru Aoyama, MASATO NAKAZANO, Shinsuke Nagasawa, Kentaro Hara, KEISUKE KOMORI, Hiroshi Tamagawa, Yukio Maezawa, Kenki Segami, Kazuki Kano, Takashi Ogata, Norio Yukawa, Yasushi Rino, Takashi Oshima
Abstract
BACKGROUND/AIM: We investigated the association of the preoperative lymphocyte-to-C-reactive-protein ratio (LCR) with gastric cancer survival and recurrence after curative treatment. PATIENTS AND METHODS: This study included 480 patients who underwent curative surgery followed by adjuvant treatment for gastric cancer between 2013 and 2017. The prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were identified. RESULTS: A LCR of 7,000 was regarded as the optimal critical point of classification, considering the 1-, 3- and 5-year survival rates. The OS rates at 3 and 5 years after surgery were 84.4% and 73.9% in the low-LCR group, respectively, and 92.4% and 87.0% in the high-LCR group, respectively, and were statistically significantly different. The RFS rates at 3 and 5 years after surgery were 78.8% and 68.7% in the low-LCR group, respectively, and 89.3% and 86.6% in the high-LCR group, respectively, with a statistically significant difference. A multivariate analysis showed that the LCR was a significant independent prognostic factor for both OS and RFS. CONCLUSION: The LCR was a significant prognostic factor for survival in patients who underwent curative treatment for gastric cancer.